Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review

IF 3.7 2区医学 Q1 UROLOGY & NEPHROLOGY

BJU International Pub Date : 2024-11-12 DOI:10.1111/bju.16577

Amit D. Raval, Stephanie Chen, Natasha Littleton, Niculae Constantinovici, Peter J. Goebell

引用次数: 0

Abstract

To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While androgen-deprivation therapy (ADT) is a primary treatment strategy for mHSPC, ADT intensification with androgen receptor pathway inhibitors (ARPIs) and/or chemotherapy is recommended by current guidelines and has improved clinical outcomes in the last decade.

查看原文本刊更多论文

雄激素剥夺疗法强化治疗转移性激素敏感性前列腺癌的实际应用：系统综述

对真实世界数据（RWD）研究进行系统性文献综述，总结转移性激素敏感性前列腺癌（mHSPC）男性患者的治疗模式。雄激素剥夺疗法（ADT）是mHSPC的主要治疗策略，而使用雄激素受体途径抑制剂（ARPIs）和/或化疗加强ADT则是现行指南的推荐疗法，并且在过去十年中改善了临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BJU International 医学-泌尿学与肾脏学

CiteScore

9.10

自引率

4.40%

发文量

262

审稿时长

1 months

期刊介绍： BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.